Protara Therapeutics에 대한 매도 수량은 투자자에게 Protara Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Protara Therapeutics (NASDAQ:TARA) 주식, 공매도 수량 보고

Protara Therapeutics

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

$BTC

MARA

MSTR

ORCL

ROKU

SOUN

TARA

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 프로타라, 마라, 트레이드 데스크, 사운드하운드 AI 및 오라클

Biotech

Health Care

Exclusives

Tech

Trading Ideas

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다. 투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics Inc

Taraxa

Tarachi Gold Corp

TARANIS RESOURCES INC ORD by Taranis Resources Inc.

Taranis Resources Inc

News

INTC

Intel Exec Says "We Need A Much Better ROI For The Investment That We've Made"

Jones Trading analyst Stephen Glagola initiates coverage on Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy rating and announces Price Target of $36.

Price Target

Initiation

Analyst Ratings

Jones Trading Initiates Coverage On Hut 8 with Buy Rating, Announces Price Target of $36

Intel Exec Says Going To Invest More In Products Under New Leadership

Shortly after ringing the New York Stock Exchange (NYSE) <a href="https://www.benzinga.com/24/12/42464081/trump-wins-time-person-of-year-rings-nyse-opening-bell-highlights-growth-ahead-the-economy-i-believe-is-going-to-be-very-strong">opening bell Thursday</a>, Donald Trump shared his thoughts on the stock market, crypto, AI and more during an impromptu interview with CNBC host Jim Cramer.
"I think you're going to see some very good days ahead," Trump <a href="https://www.cnbc.com/2024/12/12/watch-the-full-video-of-donald-trump-talking-with-jim-cramer-at-nyse.html">told</a> Cramer.
Trump&#8217;s appearance at the NYSE coincided with his being <a href="https://www.benzinga.com/media/24/12/42450651/donald-trump-to-be-named-time-person-of-the-year-beating-out-harris-musk-middleton-netanyahu-report">named Time Person of the Year</a> Thursday for the second time — the first being in 2016. 
Regarding his first steps as president in 2025, Trump said, &#8220;We have to conclude a couple of bad wars,&#8221; seemingly referring to the conflicts between Ukraine and Russia, as well as Israel and Hamas. 
Trump On Crypto: President-elect Trump also addressed the potential for a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) strategic reserve. "We're going to do something great with crypto," he added.
Trump emphasized that the U.S. must be a &#8220;leader&#8221; in cryptocurrency and artificial intelligence. 
A portion of his commentary was also on the U.S. engaging Chinese President Xi Jinping. 
"I think we're going to do very well all around,&#8221; he said.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent121124">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Trump said the U.S. has been abused as a country both economically and militarily, without citing specifics.
"We just can't let that happen," Trump said.
Thursday's bell ringing ceremony saw many business leaders and announced picks for Trump's cabinet in attendance. Cramer pointed out that Tesla CEO Elon Musk was not there.
Trump didn't share a reason why Musk wasn't present. Instead, he praised the billionaire for being a "great guy,&#8221; citing how his <a href="https://www.benzinga.com/news/management/24/12/42444955/elon-musk-first-person-worth-400-billion-as-tesla-stock-hits-new-all-time-highs-how-2024-election-helped-could-lead-to-future-gains">stock has done well </a>since the 2024 election.
The president-elect said he wants everyone to do well, including Musk and other billionaires like Mark Zuckerberg and Jeff Bezos.
Trump said Zuckerberg has already "been over to see me" and shared that he is meeting with Bezos next week.
"We want them to do well," Trump said.
Cramer echoed former President Ronald Reagan who famously <a href="https://www.reaganlibrary.gov/archives/speech/remarks-brokers-and-staff-new-york-stock-exchange-new-york-new-york">said </a>it was time to put the bear into hibernation and let the bull run when he appeared at the NYSE in 1985. Reagan referred to a bull market where stocks go higher versus a bear market where stocks go lower.
"Sounds perfect,&#8221; Trump responded to the analogy. &#8220;I can't do any better than that.&#8221;
Price Action: 
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, trades at $606.12 Thursday versus a 52-week trading range of $464.12 to $609.07. The ETF is up 28.2% year-to-date.
Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares are up 2% to $36.86 on Thursday. The media company was co-founded by Trump and owns the Truth Social platform where Trump actively posts.
Bitcoin trades at $101,413.83 Thursday, up 1% over the last 24 hours. The leading cryptocurrency recently surpassed the $100,000 level — one of several all-time highs since Trump won the 2024 election.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41798981/jim-cramer-calls-trumps-return-to-white-house-a-huge-win-for-the-stock-market">Jim Cramer Calls Trump&#8217;s Return To White House A &#8216;Huge Win For The Stock Market&#8217;</a></li>
</ul>
Image: Courtesy of the New York Stock Exchange

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Politics

Trump Talks Stocks, Bitcoin, AI, Economy With Jim Cramer: 'You're Going To See Some Very Good Days Ahead'

Ladenburg Thalmann analyst Paul Fremont initiates coverage on CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) with a Buy rating and announces Price Target of $34.5.

Ladenburg Thalmann Initiates Coverage On CenterPoint Energy with Buy Rating, Announces Price Target of $34.5

Macy&#8217;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) reported third-quarter financial results on Wednesday. Analysts are largely encouraged by the company&#8217;s progress, but remain cautious <a href="https://www.benzinga.com/news/24/12/42450838/macys-employee-hid-151-million-in-costs-over-several-years">due to margin pressures</a>.
What Happened: Macy&#8217;s reported strong headline results for the third quarter, beating analyst estimates for revenue and adjusted earnings. However, margin pressures pushed the company to lower its earnings guidance, which has analysts exercising caution in the wake of the report.
&#8220;M slightly raised its sales outlook for the year while reducing expectations for gross margin and leaving its SG&amp;A outlook largely intact, reflecting continued macro challenges, including discerning consumer spending and elevated promotional activity along with incremental delivery expense following its investigation of accounting irregularities,&#8221; Telsey Advisory Group analyst Dana Telsey said in a new note to clients.
While preparing the company&#8217;s quarterly report, Macy&#8217;s identified an issue related to delivery expenses in one of its accounts and initiated an independent investigation. The company determined that a single employee intentionally made erroneous accounting entries to hide approximately $151 million of cumulative delivery expenses.
Telsey expressed optimism about Macy&#8217;s turnaround plans involving closing underperforming stores and investing in high potential locations. The analyst believes the strategy is &#8220;reasonable&#8221; and makes sense given the structural shifts at the company.
&#8220;However, with visibility limited in the near term as macro pressures weigh, Macy&#8217;s is still facing challenges while operating in a competitive promotional space against an uncertain macro-operating environment with traffic challenges to the category,&#8221; the Telsey Advisory analyst said.
Telsey lowered earnings estimates for full-year 2024 and full-year 2025, and maintained Macy&#8217;s with a Market Perform rating and price target of $17.
Check This Out: <a href="https://www.benzinga.com/news/24/12/42450838/macys-employee-hid-151-million-in-costs-over-several-years">Macy&#8217;s Employee Hid $151 Million In Costs Over Several Years</a>
Analysts at Goldman Sachs also pointed to mounting margin pressure driven by a heightened promotional environment and higher clearance rates on cold weather products. 
Goldman analyst Brooke Roach applauded management&#8217;s plans to close stores and focus on test initiatives at First 50 locations. The analyst believes the strategy shift could mark an inflection point for comparable growth and EBITDA expansion in 2025.
&#8220;That said, we continue to closely watch M's inventory control and gross margin delivery, as this has underperformed our expectations this year and has resulted in several consecutive cuts to guidance as a result of a more value-focused consumer overall,&#8221; Roach said.
Goldman maintained a Buy rating on Macy&#8217;s despite margin concerns, as the firm expects quarterly results to improve sequentially moving forward, driven by the holiday season, store closures and the cycling of specific margin pressures such as the recently completed delivery expense investigation.
Guggenheim analyst Robert Drbul reiterated a Neutral rating following the print as he is encouraged by the strategic direction of the company, but the analyst lowered earnings estimates on expectations of a heightened promotional environment, paired with potential small packaged expense revisions. 
The Guggenheim analyst believes Macy&#8217;s will be able to close 65 stores this year given the favorable deal-making real estate environment, up from prior estimates of 55 store closures. 
&#8220;While we are encouraged by store optimization and its magnitude, as we believe it will not only be beneficial for Macy&#8217;s but for the overall industry, we await the traction of this initiative into &#8217;25 and reiterate our Neutral rating,&#8221; Drbul said.
M Price Action: Macy&#8217;s shares were down 1.93% at $16.26 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42464081/trump-wins-time-person-of-year-rings-nyse-opening-bell-highlights-growth-ahead-the-economy-i-believe-is-going-to-be-very-strong">Trump Rings NYSE Opening Bell, Says Economy &#8216;Is Going To Be Very Strong&#8217;</a></li>
</ul>
Photo: courtesy of Macy&#8217;s.

Analyst Color

Earnings

Macy's Analysts Remain Cautious After Q3 Earnings: 'Visibility Limited In The Near Term'

Barclays analyst Matt Miksic maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Underweight and lowers the price target from $125 to $118.

Barclays Maintains Underweight on Zimmer Biomet Holdings, Lowers Price Target to $118

IPOs

TTAN

ServiceTitan IPO Indicating $138.45/Share; IPO Priced At $71/Share On 8.8M Shares

Barclays analyst Matthew Bouley maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Overweight and lowers the price target from $245 to $234.

FERG

Barclays Maintains Overweight on Ferguson Enterprises, Lowers Price Target to $234

Barclays analyst Saket Kalia maintains Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) with a Overweight and lowers the price target from $675 to $645.

ADBE

Barclays Maintains Overweight on Adobe, Lowers Price Target to $645

Cadence Design Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) has outperformed the market over the past 15 years by 18.19% on an annualized basis producing an average annual return of 30.24%. Currently, Cadence Design Sys has a market capitalization of $84.64 billion. 
Buying $1000 In CDNS: If an investor had bought $1000 of CDNS stock 15 years ago, it would be worth $53,806.09 today based on a price of $308.60 for CDNS at the time of writing.
<h3>Cadence Design Sys's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734021030_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CDNS

Here's How Much You Would Have Made Owning Cadence Design Sys Stock In The Last 15 Years

Lennox Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) short percent of float has risen 16.83% since its last report. The company recently reported that it has 1.33 million shares sold short, which is 4.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lennox Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734021020_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lennox Intl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lennox Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lennox Intl's peer group average for short interest as a percentage of float is 3.38%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Lennox Intl?

TransCode Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NYSE">RNAZ</a>) short percent of float has risen 6860.8% since its last report. The company recently reported that it has 605 thousand shares sold short, which is 87.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TransCode Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734021015_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TransCode Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing TransCode Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TransCode Therapeutics's peer group average for short interest as a percentage of float is 3.92%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

RNAZ

Peering Into TransCode Therapeutics's Recent Short Interest

Dick's Sporting Goods's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) short percent of float has risen 13.02% since its last report. The company recently reported that it has 4.03 million shares sold short, which is 9.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.25 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dick's Sporting Goods Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734021010_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dick's Sporting Goods has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Dick's Sporting Goods's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dick's Sporting Goods's peer group average for short interest as a percentage of float is 11.73%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(DKS) - Analyzing Dick's Sporting Goods's Short Interest

RBC Capital analyst Steven Shemesh maintains Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) with a Sector Perform and raises the price target from $291 to $292.

RBC Capital Maintains Sector Perform on Lowe's Companies, Raises Price Target to $292

The $300 Billion Dementia Care Revolution: Wall Street's Next Tesla-Sized Opportunity
A $300 billion government program is about to transform dementia care into one of the hottest investment opportunities of the decade – and almost no one is talking about it.
<h2 class="wp-block-heading">The Big Picture</h2>
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/38689398/">6.9 million Americans</a> currently live with dementia</li>
<li>11.5 million unpaid family caregivers provide support</li>
<li>Both numbers expected to <a href="https://milkeninstitute.org/content-hub/research-and-reports/reports/projected-prevalence-and-cost-dementia-2022-update">double by 2050</a></li>
<li>Healthcare systems severely underprepared for surge</li>
</ul>
A little-known <a href="https://www.cms.gov/priorities/innovation/innovation-models/guide" target="_blank" rel="noopener">Medicare initiative called GUIDE</a> (Guiding an Improved Dementia Experience) was launched in the late summer of 2024. This program will unleash a tidal wave of funding into the dementia care sector. Yet, outside of niche <a href="https://www.boomerventuresummit.com/">longevity circles</a>, the immense opportunity remains largely unknown.
America faces a <a href="https://www.careyaya.org/resources/blog/aging-america-addressing-the-growing-demand-for-neurological-care">dementia crisis</a> of staggering proportions. Our rapidly aging population and <a href="https://www.neurologylive.com/view/how-america-neurological-care-crisis-reshaping-medicare-what-that-means-for-you">rising dementia rates</a> mean millions of family members will be forced to exit the workforce to manage caregiving, creating a massive economic drain. Current healthcare systems are woefully unprepared for the coming surge in dementia cases.
<h2 class="wp-block-heading">Enter Medicare GUIDE</h2>
Medicare&#8217;s new GUIDE (Guiding an Improved Dementia Experience) program launched last month. It partners with <a href="https://www.careyaya.org/resources/blog/dementia-memory-care-emory-atlanta" target="_blank" rel="noopener">hospitals</a> and primary care providers and offers a potential $40 billion in annual disbursements over eight years. The initiative provides up to $6,000 per year per patient for <a href="https://www.cms.gov/blog/guiding-improved-dementia-experience-clearing-path-comprehensive-high-quality-dementia-care" target="_blank" rel="noopener">care navigation and respite services</a>. The goal is to keep patients at home longer, reduce the burden on family caregivers, and save Medicare billions in institutional care costs.
$40 billion a year is a staggering sum of fresh money flowing into an industry ripe for innovation. The initiative reminds me of the <a href="https://thehill.com/opinion/energy-environment/573148-dept-of-energys-loan-program-helped-tesla-now-it-needs-to-help-low/">billions of dollars in loans made by the Department of Energy to spur clean energy innovation</a>. That led to <a href="https://www.energy.gov/lpo/tesla">the rise of Tesla</a>, creating the investment opportunity of a lifetime. With the GUIDE initiative, the government is now signaling dementia care as a national priority. The upcoming wave of spending could be even more significant, creating Tesla-sized opportunities for those who move early.
Opportunities abound in home care technology, AI-powered diagnostics, novel therapies and interventions, and even financial products for long-term care planning.
Investors and entrepreneurs should act now for several reasons:
1. The market is vast and growing, with an unmet need that can&#8217;t be ignored.
2. Government backing of tens of billions annually creates a significant tailwind.
3. The technological frontier, particularly in <a href="https://www.neurologylive.com/view/ai-powered-neurotech-could-revolutionize-dementia-care-unlock-communications">AI</a> and <a href="https://www.careyaya.org/resources/blog/openmind-neurotech-initiative">neurotechnology</a>, opens new possibilities daily for helping those with dementia.
4. The pressing need for dementia care transcends party lines.
This is a rare chance to generate significant returns while profoundly impacting millions of lives. Acting on this opportunity is what real ESG investing looks like – creating measurable social impact alongside financial returns.
The dementia care revolution represents a rare confluence of social impact and massive profit potential. Early movers in this space could capture Tesla-sized returns while addressing one of healthcare&#8217;s most pressing challenges.
Smart money is already moving. The question isn&#8217;t if this market will explode but who will dominate it. Will you be at the forefront?

Opinion

America's $300 Billion Moonshot: The Medicare Guide Program

RBC Capital analyst Brad Erickson reiterates Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Outperform and maintains $35 price target.

Reiteration

MTCH

RBC Capital Reiterates Outperform on Match Group, Maintains $35 Price Target

UBS analyst Josh Silverstein maintains Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) with a Buy and lowers the price target from $149 to $147.

UBS Maintains Buy on Exxon Mobil, Lowers Price Target to $147

Evercore ISI Group analyst Greg Melich maintains Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) with a In-Line and raises the price target from $270 to $290.

Evercore ISI Group Maintains In-Line on Lowe's Companies, Raises Price Target to $290

Artificial intelligence (AI) has made significant strides in the banking sector in recent years. From customer service to fraud detection, AI is transforming how banks operate. With the use of machine learning algorithms, banks can analyze vast amounts of data and make informed decisions. However, as with any new technology, there is both promise and peril associated with AI in banking.
The increased reliance on artificial intelligence has pros and cons for the banking sector, and more widely to their customers. While widespread adoption of AI and machine learning throughout the finance sector may still be years away. Now is the time to explore the early results. With that in mind, here&#8217;s a look at potential positives and negatives of letting the robots take the financial reins.
 Promises of AI in Banking
Improvements in the Customer Experience
Banks live and die on their customer service, and depositors who feel disregarded or disrespected are likely to vote with their dollars and take their business elsewhere. Providing stellar customer service while keeping costs down has been an ongoing challenge for banks, and it&#8217;s something AI could one day revolutionize.
AI has the potential to revolutionize the customer experience in banking. Chatbots and virtual assistants can handle customer queries, provide account information, and offer personalized recommendations based on customer preferences. This allows banks to provide 24/7 customer service without the need for human intervention.
Enhanced Fraud Detection
With electronic transactions becoming a greater share of banking business, fraud detection is an indispensable part of doing business. The sheer volume of daily transactions makes human scrutiny impossible, but AI can handle the load far more efficiently and effectively.
Fraud is a major concern for banks, and AI can help banks detect fraudulent activity in real time. Machine learning algorithms can analyze patterns in transactions and identify suspicious behavior. This can help prevent fraud before it occurs, saving banks and their customers significant amounts of money.
Increases in Efficiency
Many banks operate on razor-thin margins, and rising employment costs only make the problem worse. Those in the financial sector are always looking for ways to ramp up efficiency and do more with less, and that&#8217;s where artificial intelligence comes into play.
Artificial intelligence can potentially automate many of the routine tasks that bank employees perform. This includes data entry, record keeping, and compliance checks. By automating these tasks, banks can improve efficiency and reduce costs. This can also free up employees to focus on higher-level tasks that require human expertise.
More Effective Risk Management
Risk management is a big problem in the banking sector &#8212; one need only look at the rapid collapse of Silicon Valley Bank for proof of that. Forensic examination of the bank and its deposits showed that nearly 90% of deposits exceeded the $250,000 FDIC insurance limit &#8212; a fact that somehow escaped the scrutiny of all the human regulators.
AI has the potential to help banks manage risk by providing more accurate predictions and insights. Machine learning algorithms can analyze historical data to identify patterns and trends that may indicate potential risks. This can help banks make better-informed decisions and reduce the likelihood of losses.
 Perils of AI in Banking
Potential Bias
AI critics like to point out that machine learning is only as good as its teacher. Even well-meaning data scientists may introduce their own thoughts, feelings, and biases without knowing it, giving their AI creations a skewed vision of reality and creating a number of problems down the line.
One of the biggest perils of AI in banking is the potential for bias. AI systems are only as unbiased as the data they are trained on. If the data used to train an AI system is biased, it will reflect that bias in its decision-making. This can lead to discrimination against certain groups of people, such as minorities or low-income individuals.
Security Risks
From the early days of the text-based internet to the latest social media iterations, every form of online technology has been hacked. Hacking is an especially pernicious problem, one that to date has not been solved.
Like their less intelligent counterparts, artificial intelligence and machine learning systems can also be vulnerable to cyber-attacks, which can result in the loss of sensitive customer information. Banks must ensure that their AI systems are secure and that they are not vulnerable to attacks.
Lack of Transparency
One of the hallmarks of artificial intelligence and machine learning is that the algorithms build on themselves, advancing their abilities along the way. Over time the advances have the potential to exceed the abilities of their human programmers, creating a troubling lack of transparency.
AI systems can be complex, and it can be difficult to understand how they make decisions. This lack of transparency can be problematic, particularly regarding compliance and regulatory requirements. Banks must ensure that their AI systems are transparent and that they are able to explain how they arrive at their decisions.
Job Losses
The AI revolution has often been likened to the industrial revolution. Proponents see that comparison as proof of a great leap forward, while critics point to the enormous societal disruptions that followed the sudden shift from subsistence farming to large-scale factories.
As AI systems automate many of the routine tasks performed by bank employees, there is a risk that jobs may be lost. This could have a significant impact on bank employees, particularly those in lower-level roles.
Artificial intelligence can potentially revolutionize the banking sector, but it has risks. Banks must ensure their AI systems are secure, transparent, and unbiased. They must also ensure that their employees are trained to work alongside AI systems rather than being replaced by them. Ultimately, the success of AI in banking will depend on how well banks can balance the promise and peril of this exciting technology.

Financing

AI and Your Money: The Promise and Peril of Artificial Intelligence in the Banking and Finance Sector

The latest update is out from Protara Therapeutics ( ($TARA) ). Protara Therapeutics presented promising interim results from its Phase 2 ADVANCED-...

Protara Therapeutics Reports Promising Phase 2 Trial Results

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Protara Therapeutics (TARA – Research Report), with a price...

Promising Efficacy of TARA-002 Positions Protara Therapeutics as a Compelling Buy for HR-NMIBC Treatment

Protara announces proposed offering of common stock

Protara Therapeutics (TARA) announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of issuing co...

Protara Therapeutics announces common stock offering, no amount given

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – C3.ai (AI)&nbsp;up 3.9% Vail ...

Closing Bell Movers: Oracle slips 8% after Q2 earnings miss, disappointing guide

Protara Therapeutics drops 6%, prices $100M offering

The deal range was $6.00-$6.50. TD Cowen, Cantor Fitzgerald, LifeSci Capital, Oppenheimer and Scotiabank acted as joint book running managers for t...

Protara Therapeutics 13.69M share Spot Secondary priced at $6.25

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Protara Therapeutics: Carving New Roads In Bladder Cancer

An announcement from Protara Therapeutics ( ($TARA) ) is now available. Protara Therapeutics has announced the closing of a public offering of comm...

Protara Therapeutics Raises $100M in Stock Offering

ASYS

BMEA

BRZE

CASY

CMRX

FLNC

YEXT

Press Releases

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Announces Proposed Public Offering

Protara Announces Pricing of $100 Million Public Offering

Markets

Protara Announces Closing of $100 Million Public Offering

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Aligos Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cibus

Elutia

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Immunic

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Leap Therapeutics

MediciNova

Monopar Therapeutics

Puma Biotechnology

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Regulus Therapeutics

Skye Bioscience

TriSalus Life Sciences, Inc. - Common Stock

Comments

Protara Therapeutics

매도 수량

Protara Therapeutics (NASDAQ:TARA) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌